[Comparative trials on sultopride and fluanisone].
A therapeutic trial has been carried out on 50 patients, most of them being hospitalized, in order to compare the characteristics of a new benzamide, Sultopride, to those of a butyrophenone, Fluanisone, for the treatment of important and chronic agitation states. Clinically, they were essentially psychotic states, with dissociation. From this trial it appeared that sultopride is superior to fluanizone with regard to their sedative effects and that it has specific characteristics: a very powerful antipsychotic action, an increasing efficiency over time, as well as an improvement of incoercible agitation in children. Thus, the present trial has checked out the well-known sedative action of Fluanisone, and has revealed a new major antipsychotic drug, Sultopride, the superiority of which lies on a much wider therapeutic field.
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001634:Bibliographies as Topic; D002090:Butyrophenones; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D002090:Butyrophenones; C005014:fluanisone; D013469:Sulpiride
Essai comparatif du sultopride et de la fluanisone.